Genzyme and Relational Investors: Science and Business Collide?

內容大綱
The chairman and CEO of the Genzyme Corporation, one the country's top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large hedge fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this "activist" investor with a track record of forcing out CEOs.
涵蓋主題
新增
新增